TargetMol

HPV16 E7 (86-93) acetate

Product Code:
 
TAR-TP1554L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TP1554L-1mg1mg£174.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1554L-5mg5mg£283.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1554L-10mg10mg£373.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1554L-25mg25mg£579.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1554L-50mg50mg£780.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1554L-100mg100mg£1,058.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1554L-500mg500mg£2,054.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
HPV16 E7 (86-93) acetate is a derived peptide of human leukocyte antigen A2.1 restricted HPV16 E7 with immunogenic property in cervical carcinomas.
CAS:
TP1554L
Formula:
C39H70N8O12S
Molecular Weight:
875.08
Purity:
0.98
SMILES:
C[C@@H](O)[C@H](N)C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@@H](CS)C(N1CCC[C@H]1C(N[C@@H]([C@@H](C)CC)C(O)=O)=O)=O)=O)C(C)C)=O)[C@@H](C)CC)=O)=O)CC(C)C)=O.CC(O)=O

References

Cheng WF, et al. Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations. Immunology. 2005 May;115(1):136-49. Hoffmann TK, et al. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer. 2006 Apr 15;118(8):1984-91.